Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment

Annals of the Rheumatic Diseases

Volumn 76, Issue 10, 2017, Pages 1747-1750

  Belkhir, Rakiba ^a   Le Burel, Sébastien ^a   Dunogeant, Laetitia ^b   Marabelle, Aurélien ^c   Hollebecque, Antoine ^c   Besse, Benjamin ^c   Leary, Alexandra ^c   Voisin, Anne Laure ^c   Pontoizeau, Clémence ^d   Coutte, Laetitia ^e   Pertuiset, Edouard ^f   Mouterde, Gaël ^g   Fain, Olivier ^h   Lambotte, Olivier ^a,i   Mariette, Xavier ^a,j  

^a BICÊTRE HOSPITAL   (France)

^b CENTRE HOSPITALIER DU PAYS D AIX   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d Centre Hospitalier de Saint Brieuc   (France)

^e Université Paris Saclay ^*  (France)

^f CENTRE HOSPITALIER RENÉ DUBOS   (France)

^g LAPEYRONIE HOSPITAL   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^j UNIVERSITÉ PARIS SACLAY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID DERIVATIVE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DRUG; HYDROXYCHLOROQUINE; IPILIMUMAB; METHOTREXATE; NIVOLUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PEMBROLIZUMAB; PREDNISONE; PROGRAMMED DEATH 1 RECEPTOR; ANTIBODY; ANTINEOPLASTIC AGENT; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1;

ADULT; AGED; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNE DISEASE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; DRUG EXPOSURE; FEMALE; HUMAN; MALE; MALIGNANT NEOPLASM; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OBSERVATIONAL STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; CHEMICALLY INDUCED; IMMUNOLOGY; POLYMYALGIA RHEUMATICA;

AGED; AGED, 80 AND OVER; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; ARTHRITIS, RHEUMATOID; CTLA-4 ANTIGEN; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; POLYMYALGIA RHEUMATICA; PROGRAMMED CELL DEATH 1 RECEPTOR; RETROSPECTIVE STUDIES;

EID: 85024910567     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2017-211216     Document Type: Article

References (22)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
2. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54.
3. Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016; 54: 139-48.
4. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 2016; 44: 51-60.
5. Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016; 27: 559-74.
6. Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2016; 2: 234-40.
7. Bonigen J, Raynaud-Donzel C, Hureaux J, et al. Anti-PD1-induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol 2017; 31.
8. Calabrese L, Velcheti V. Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases. Ann Rheum Dis 2017; 76: 1-3.
9. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69: 1580-8.
10. Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 2012: 71:484-92.
11. Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 2017; 76: 43-50.
12. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50: 380-6.
13. Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141-51.
14. Ceeraz S, Nowak EC, Burns CM, et al. Immune checkpoint receptors in regulating immune reactivity in rheumatic disease. Arthritis Res Ther 2014; 16: 469.
15. Syrigos K, Tsagouli S, Grapsa D. Nivolumab-induced recurrence of rheumatoid arthritis in a patient with advanced non-small cell lung cancer: a case report. Ann Intern Med 2016; 165: 894-5.
16. Goldstein BL, Gedmintas L, Todd DJ. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4. Arthritis Rheumatol 2014; 66: 768-9.
17. Garel B, Kramkimel N, Trouvin AP, et al. Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma. Joint Bone Spine 2017; 84.
18. Zhang H, Watanabe R, Berry GJ, et al. Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proc Natl Acad Sci U S A 2017; 114: E970-E979.
19. Le Burel S, Champiat S, Routier E, et al. Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy. Ann Rheum Dis 2017.
20. Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or Major toxicity with ipilimumab. Annals of Oncology 2016: mdw443.
21. Satzger I, Meier A, Schenck F, et al. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha. Int J Cancer 2007; 121: 2562-6.
22. Hua C, Boussemart L, Mateus C, et al. Association of Vitiligo with tumor response in patients with metastatic melanoma treated with Pembrolizumab. JAMA Dermatol 2016; 152: 45-51.